Regulators Moving Ahead Of Industry In China? Officials, Execs Weigh In

Shorter INDs But Trial Delays

While regulators are steaming ahead to accelerate clinical trial and product approvals, China's pharma industry still lacks innovation. Underlying the hot investment, multi-million deals and IPOs is a lingering reliance on 'fast-following,' regulators and pharma execs tell the DIA China meeting.

DIA China 2021 meeting
REGULATORS MOVE FAST AND INDUSTRY NEEDS TO DO ITS PART, SAYS CHINA'S TOP DRUG REVIEW OFFICIAL • Source: Pink Sheet/Brian Yang

Among the many words used to describe the current Chinese pharma market, from “hot” to “crowded” to "booming", the most common is “exciting.”

After all, China’s health sector has quickly emerged from the COVID-19 pandemic and is rebounding strongly, a fact underscored by the packed venues during the Drug Information Association China annual conference, one of the largest gatherings of top

More from China

More from Asia